Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PRQR

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

StockNews.com · Feb 28, 2024

4 Biotech Stocks With Massive Buy Potential

The biotech sector is poised for robust long-term growth, driven by significant developments in drug approvals, innovative therapies, and government-backed initiatives. Hence, investors might consider buying fundamentally solid biotech stocks ProQR Therapeutics (PRQR), Foghorn Therapeutics (FHTX), Harmony Biosciences (HRMY), and Organogenesis Holdings (ORGO) with massive buy potential. Keep reading.

StockNews.com · Jan 30, 2024

2 Biotech Stocks to Buy, 1 to Sell Now

The biotech industry is well-positioned for long-term growth thanks to increasing demand for quality healthcare, a rapidly aging population, and rising chronic diseases. Therefore, buying fundamentally strong biotech stocks Entrada Therapeutics (TRDA) and ProQR Therapeutics N.V. (PRQR) could be wise. On the other hand, one should consider selling 4D Molecular…

StockNews.com · Jun 28, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Expert Ratings for ProQR Therapeutics

Within the last quarter, ProQR Therapeutics (NASDAQ:PRQR) has observed the following analyst ratings:

Benzinga · May 6, 2022

ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce

ProQR Therapeutics N.V. (NASDAQ:PRQR) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform. The Company will suspend the development of QR-1123 for autosomal dominant retinitis pigmentosa, QR-504a for Fuchs endothelial corneal dystrophy, and all other Inherited Retinal diseases (IRD)-related research activities. ProQR will implement…

Benzinga · Apr 13, 2022

Where ProQR Therapeutics Stands With Analysts

Analysts have provided the following ratings for ProQR Therapeutics (NASDAQ:PRQR) within the last quarter:

Benzinga · Feb 14, 2022

ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder

ProQR Therapeutics N.V. (NASDAQ: PRQR) shares are plunging after

Benzinga · Feb 11, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

Corcept Therapeutics Incorporated

14 stories

Organogenesis Holdings Inc

14 stories

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,412 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.